Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma

Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02209376). We report the case of a 59-year-old patie...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Durgin, Joseph S., Henderson, Fraser, Nasrallah, MacLean P., Mohan, Suyash, Wang, Sumei, Lacey, Simon F., Melenhorst, Jan Joseph, Desai, Arati S., Lee, John Y. K., Maus, Marcela V., June, Carl H., Brem, Steven, O’Connor, Roddy S., Binder, Zev, O’Rourke, Donald M.
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2021
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8138201/
https://ncbi.nlm.nih.gov/pubmed/34026647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.669071
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires